Lexaria Bioscience Equity Ratio
The Equity Ratio of Lexaria Bioscience (LEXX) as of Oct 13, 2026 is 71.61 %. In the previous year, Equity Ratio was 90.62 % — a change of -20.98% (lower).
Get this data via API
Financial Data API
Equity Ratio
71.61 %
YoY
-20.98%
Last updated:
The Lexaria Bioscience Equity Ratio history
3 Years
10 Years
25 Years
Max
| YEAR | Equity Ratio | YoY |
|---|---|---|
| 71.61 % | -20.98% | |
| 90.62 % | -8.19% | |
| 98.71 % | -2.72% | |
| 101.47 % | +1.48% | |
| 99.99 % | +11.99% | |
| 89.29 % | +0.23% | |
| 89.08 % | -9.29% | |
| 98.21 % | -6.57% | |
| 105.11 % | +123.87% | |
| 46.95 % | -56.74% | |
| 108.53 % | +84.77% | |
| 58.74 % | — |
Lexaria Bioscience Stock analysis
Frequently Asked Questions about Lexaria Bioscience stock
Equity Ratio of Lexaria Bioscience is 71.61 % in 2025.
Equity Ratio of Lexaria Bioscience changed from 90.62 % to 71.61 %, representing a -20.98% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Equity Ratio Lexaria Bioscience since 2006 – with annual values, charts, and detailed analysis.
The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Lexaria Bioscience with sector peers and the industry average to assess whether it is attractive.
Leverage — Lexaria Bioscience
All Key Metrics — Lexaria Bioscience
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth